|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's range||12.19 - 12.73|
|52-week range||12.19 - 22.40|
|Beta (5Y monthly)||1.38|
|PE ratio (TTM)||N/A|
|Earnings date||03 Aug 2021 - 09 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||34.25|
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The White House's plans to address the U.S. opioid crisis could be good news for Heron Therapeutics and Collegium Pharmaceutical, makers of safer pain management drugs.
Shares of Heron Therapeutics (NASDAQ: HRTX) were jumping 7.3% as of 3:08 p.m. EDT on Monday after rising as much as 13% earlier in the day. Heron announced Q1 revenue of $20 million, down 21% year over year. The average analysts' estimate projected Q1 revenue of $25.7 million and a loss of $0.57 per share.